- 0
Biologic drugs have transformed how we treat cancer, autoimmune diseases, and rare conditions. But while these medications save lives, their prices often leave patients struggling to afford them. The reason? A legal and regulatory system designed to delay competition from biosimilars - cheaper, highly similar versions of these complex drugs. In the U.S., that delay can last up to 12 years after a biologic first hits the market. That’s not a mistake. It’s the rule.
How Long Must You Wait for a Biosimilar?
The Biologics Price Competition and Innovation Act (BPCIA) of 2009 set the rules. Under this law, once the FDA approves a new biologic - say, Humira or Enbrel - the manufacturer gets two layers of protection. First, there’s a 4-year data exclusivity period. During this time, no biosimilar company can even submit an application to the FDA. Then comes the 12-year market exclusivity period. Even if a biosimilar application gets submitted after year four, the FDA can’t approve it until 12 years have passed.
This isn’t just paperwork. It’s a 12-year monopoly. And it’s longer than almost anywhere else. In the European Union, biosimilars can enter after 10 years of data protection plus one year of market exclusivity - 11 total. Japan matches the U.S. at 12 years. South Korea gives 10 years of data protection but no extra market delay. The U.S. system was built to reward innovation, but it’s also built to delay competition.
The Patent Dance: A Legal Maze
Even after the 12-year clock starts ticking, biosimilar companies face another hurdle: the "patent dance." This isn’t a dance at all - it’s a multi-step legal process that can drag on for years.
When a biosimilar maker submits its application, it must send all its manufacturing and clinical data to the original drugmaker within 20 days. The original company then has 60 days to list every patent they think might be violated. The biosimilar maker responds with a detailed legal argument for why each patent is invalid or doesn’t apply. Then both sides enter 15 days of negotiations to pick which patents to fight over in court.
It sounds fair. But in practice, it’s a tool for delay. Take Humira. Its main patent expired in 2016. But AbbVie, the maker, piled on 166 additional patents - many covering minor changes in dosage, delivery, or manufacturing. Each one became a new legal battle. By the time the first U.S. biosimilar entered in 2023, Humira had been on the market for 22 years. In Europe, biosimilars started appearing in 2018. American patients paid 300% more during that gap.
Why Are So Few Biosimilars Coming?
Developing a biosimilar isn’t like making a generic pill. You can’t just copy the formula. Biologics are made from living cells - proteins, antibodies, sometimes entire cell therapies. Even tiny changes in how they’re made can affect safety or effectiveness. So manufacturers must prove they’re "highly similar" with "no clinically meaningful differences." That means expensive lab work, complex clinical trials, and years of testing.
According to Pfizer’s 2022 manufacturing report, it takes 5 to 9 years and over $100 million to bring a biosimilar to market. For the most complex biologics - like antibody-drug conjugates or gene therapies - costs can hit $250 million. That’s 50 to 100 times more than a typical generic drug.
And the payoff isn’t always worth it. A 2023 report from the Biosimilars Council found that 88% of biologics with orphan drug status - meaning they treat rare diseases - have no biosimilars in development. Why? Because the patient pool is small. Companies don’t see enough profit to justify the risk. Meanwhile, 118 biologics are set to lose patent protection between 2025 and 2034. But only 12 of them currently have biosimilars being developed.
The Cost to Patients
Patients aren’t just paying more. They’re skipping treatment entirely. A 2022 survey by the National Community Pharmacists Association found that 63% of pharmacists had patients who stopped using their biologic because they couldn’t afford it. One patient with rheumatoid arthritis might pay $2,000 a month for Humira in the U.S. - the same drug costs $500 in Germany after biosimilars entered.
Between 2012 and 2022, Humira’s list price in the U.S. jumped 470%. In Europe, it stayed flat. That gap isn’t about innovation. It’s about monopoly power. The Congressional Budget Office estimated that if we removed the barriers slowing biosimilars, the U.S. could save $158 billion over the next decade. Under current rules? Just $71 billion.
What’s Being Done?
The FDA has tried. Their 2022 Biosimilars Action Plan promised better communication, faster reviews, and more market support. But progress has been slow. Since 2015, the U.S. has approved only 38 biosimilars. Europe has approved 88. And while the FDA is working on streamlining the process, Congress hasn’t passed meaningful reform. A bill in 2022 to reduce regulatory burdens stalled in committee.
Meanwhile, innovator companies keep filing new patents. Some are legitimate. Many are not. The system rewards legal strategy over patient access. And with 16 complex biologics - including next-generation cancer drugs and gene therapies - set to expire between 2025 and 2034, we’re staring at another wave of delayed competition.
What’s Next?
There’s no magic fix. But change is possible. If the U.S. shortened the exclusivity period to 10 years - matching Europe - biosimilars would enter years earlier. If regulators gave more clarity on what "highly similar" really means, developers could cut costs. If payers and pharmacies started pushing biosimilars as much as generics, demand would rise.
Right now, the system protects profits more than patients. But the science is here. The demand is real. And the cost of waiting is measured in lives - and lost treatments.
How long does it take for a biosimilar to enter the U.S. market after a biologic is approved?
Under U.S. law, a biosimilar cannot be approved until 12 years after the original biologic was first approved by the FDA. However, biosimilar manufacturers can submit their application after 4 years. The 12-year clock starts on the date of the reference product’s first licensure, and this period can be extended by 6 months if the manufacturer conducts pediatric studies.
What’s the difference between a biosimilar and a generic drug?
Generics are exact copies of small-molecule drugs, made from chemical compounds. Biosimilars are highly similar versions of complex biologic drugs made from living cells. They’re not identical - even small changes in manufacturing can affect their behavior. That’s why biosimilars require more testing, including clinical trials, to prove they work the same way in patients.
Why are there so few biosimilars for rare disease drugs?
Most rare disease biologics have small patient populations, which means limited sales potential. Developing a biosimilar costs over $100 million and takes 5-9 years. For drugs treating only a few hundred patients, that investment rarely makes financial sense. As a result, 88% of expiring biologics with orphan drug status have no biosimilars in development.
Can biosimilars be used interchangeably with the original biologic?
The FDA can designate a biosimilar as "interchangeable," meaning it can be substituted for the original without a doctor’s approval. But so far, only a handful of biosimilars have received this status. Most require a prescription for the specific product. Pharmacists cannot automatically swap them unless they’re labeled as interchangeable.
Do other countries have shorter exclusivity periods?
Yes. The European Union offers 10 years of data exclusivity and 1 year of market exclusivity - 11 total. Japan matches the U.S. at 12 years. South Korea gives 10 years of data exclusivity with no additional market delay. The U.S. has one of the longest exclusivity periods in the world, which is why many biologics enter European markets years before the U.S.